4Dm2m

broadly neutralizing CD4-antibody fusion protein against HIV-1

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

1.	Infections 05/01/2016 - "The new 4Dm2m variants are promising candidates for clinical development to prevent or treat HIV-1 infection. " 06/21/2017 - "These results indicate that the gp120-targeting bispecific multivalent proteins 2Dm2m and 4Dm2m have potential for further development as HIV-1 inactivator-based antiviral drugs for use in the clinic, either alone or in combination with a gp41-targeting HIV-1 fusion inhibitor such as T20, to treat patients with HIV-1 infection and AIDS."
2.	Acquired Immunodeficiency Syndrome (AIDS) 06/21/2017 - "These results indicate that the gp120-targeting bispecific multivalent proteins 2Dm2m and 4Dm2m have potential for further development as HIV-1 inactivator-based antiviral drugs for use in the clinic, either alone or in combination with a gp41-targeting HIV-1 fusion inhibitor such as T20, to treat patients with HIV-1 infection and AIDS."

1.	Proteins (Proteins, Gene)
2.	Antiviral Agents (Antivirals)